The Victoria Advocate15d
Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%
Participants using Zepbound lost 50.3 lbs (22.8 kg) and participants on Wegovy lost 33.1 lbs (15.0 kg) SURMOUNT-5 compared Zepbound, a dual GIP and GLP-1 receptor agonist, to Wegovy, a mono GLP ...
Ro to offer lower-price vials of weight loss drug Zepbound by teaming up with Eli Lilly
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
The Washington Post15d
Zepbound tops Wegovy for weight loss in Eli Lilly study
Shares of Eli Lilly climbed Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo Nordisk.
The Washington Post14d
Eli Lilly invests $3B to expand Wisconsin factory to help meet demand for Mounjaro, Zepbound
Mounjaro and Zepbound. Those drugs brought in a combined $4.4 billion in sales for Lilly in this year’s third quarter. The drugmaker plans to start construction of the expansion next year.
CNN14d
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly. In a head-to-head comparison of the two GLP-1 drugs ...
USA Today14d
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...
AOL14d
Zepbound Leads to More Weight Loss Than Wegovy in Head-to-Head Clinical Trial
Lilly officials said 31% of people taking Zepbound lost at least 25% of their body weight compared to 16% of study participants who took Wegovy. Experts note that weight loss drugs can only be ...